Potential Impact of Biologically Derived Hyaluronic Acid on Quality of Life in Patients with Knee Osteoarthritis in the United States.
Knee osteoarthritis is one of the leading causes of disability in the world. Intra-articular hyaluronic acid (IA-HA) is a treatment modality that provides a minimally invasive treatment option for the management of osteoarthritis-related symptoms. This study examined the current and potential economic impact of using a biologically derived, high molecular weight hyaluronic acid preparation (Euflexxa) on the US population for the management of knee osteoarthritis.



A model was developed to estimate the total number of patients with symptomatic knee osteoarthritis in the US in 2015, distributed by Kellgren-Lawrence (K-L) grade, and the number of people living with total knee arthroplasty (TKA). The potential utility of Euflexxa was applied to this model population to determine the current and potential impact of the treatment as the total number of quality adjusted life years (QALY) saved within the US population.



There are approximately 12 million people currently suffering from symptomatic knee osteoarthritis in the US, and approximately 5 million living with TKA. It was estimated that, with a target treatment group of K-L grades 2-3, there are approximately 4 million patients eligible for treatment with a high molecular weight intra-articular hyaluronic acid injection. With current use, it is estimated that Euflexxa can save 36,730 QALY/year among the US population, and has the potential to save an additional 369,181 QALY/year if used by all eligible patients.



This study demonstrates that more widely used, biologically derived, high molecular weight IA-HAs, such as Euflexxa, have the potential to save a substantial number of QALYs among the US population with symptomatic knee osteoarthritis.



Ferring Pharmaceuticals Inc.
Department of Orthopaedics and Rehabilitation, New York Presbyterian Queens, New York, NY, USA. Jeffrey.Rosen@nyumc.org.|Department of Clinical Orthopaedic Surgery, Weill Medical College of Cornell University, New York, NY, USA. Jeffrey.Rosen@nyumc.org.
Jeffrey
J
Rosen
Sancheti Institute for Orthopaedics and Rehabilitation, Pune, Maharashtra, India.
Parag
P
Sancheti
Ferring Pharmaceuticals Inc., Parsippany, NJ, USA.
Anke
A
Fierlinger
Ferring Pharmaceuticals Inc., Parsippany, NJ, USA.
Faizan
F
Niazi
Division of Orthopaedics, Department of Surgery, Centre for Evidence-Based Orthopaedics, McMaster University, Hamilton, ON, USA.
Herman
H
Johal
Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, MI, USA.
Asheesh
A
Bedi
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use*; D007270:Injections, Intra-Articular; D008297:Male; D008875:Middle Aged; D020370:Osteoarthritis, Knee / Q000188:drug therapy* / Q000453:epidemiology; D011788:Quality of Life; D014481:United States / Q000453:epidemiology
D006820:Hyaluronic Acid
Economic; Euflexxa; Hyaluronic acid; Knee; Orthopaedics; Osteoarthritis